{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:30Z","timestamp":1787028510178,"version":"build-2736575974"},"reference-count":107,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Council, Taiwan","award":["NSTC 111-2326-B-182A-003-"],"award-info":[{"award-number":["NSTC 111-2326-B-182A-003-"]}]},{"name":"National Science and Technology Council, Taiwan","award":["111-2314-B-182A-113-MY3"],"award-info":[{"award-number":["111-2314-B-182A-113-MY3"]}]},{"name":"National Science and Technology Council, Taiwan","award":["CORPG2M0031"],"award-info":[{"award-number":["CORPG2M0031"]}]},{"name":"National Science and Technology Council, Taiwan","award":["CORPG3M0221-2"],"award-info":[{"award-number":["CORPG3M0221-2"]}]},{"name":"Chang Gung Memorial Hospital","award":["NSTC 111-2326-B-182A-003-"],"award-info":[{"award-number":["NSTC 111-2326-B-182A-003-"]}]},{"name":"Chang Gung Memorial Hospital","award":["111-2314-B-182A-113-MY3"],"award-info":[{"award-number":["111-2314-B-182A-113-MY3"]}]},{"name":"Chang Gung Memorial Hospital","award":["CORPG2M0031"],"award-info":[{"award-number":["CORPG2M0031"]}]},{"name":"Chang Gung Memorial Hospital","award":["CORPG3M0221-2"],"award-info":[{"award-number":["CORPG3M0221-2"]}]},{"name":"CGMH-XMCG Joint Research Program","award":["NSTC 111-2326-B-182A-003-"],"award-info":[{"award-number":["NSTC 111-2326-B-182A-003-"]}]},{"name":"CGMH-XMCG Joint Research Program","award":["111-2314-B-182A-113-MY3"],"award-info":[{"award-number":["111-2314-B-182A-113-MY3"]}]},{"name":"CGMH-XMCG Joint Research Program","award":["CORPG2M0031"],"award-info":[{"award-number":["CORPG2M0031"]}]},{"name":"CGMH-XMCG Joint Research Program","award":["CORPG3M0221-2"],"award-info":[{"award-number":["CORPG3M0221-2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The efficacy and the safety of psoriasis medications have been proved in trials, but unideal responses and side effects are noted in clinical practice. Genetic predisposition is known to contribute to the pathogenesis of psoriasis. Hence, pharmacogenomics gives the hint of predictive treatment response individually. This review highlights the current pharmacogenetic and pharmacogenomic studies of medical therapy in psoriasis. HLA-Cw*06 status remains the most promising predictive treatment response in certain drugs. Numerous genetic variants (such as ABC transporter, DNMT3b, MTHFR, ANKLE1, IL-12B, IL-23R, MALT1, CDKAL1, IL17RA, IL1B, LY96, TLR2, etc.) are also found to be associated with treatment response for methotrexate, cyclosporin, acitretin, anti-TNF, anti-IL-12\/23, anti-IL-17, anti-PDE4 agents, and topical therapy. Due to the high throughput sequencing technologies and the dramatic increase in sequencing cost, pharmacogenomic tests prior to treatment by whole exome sequencing or whole genome sequencing may be applied in clinical in the future. Further investigations are necessary to manifest potential genetic markers for psoriasis treatments.<\/jats:p>","DOI":"10.3390\/ijms24087329","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T03:14:09Z","timestamp":1681701249000},"page":"7329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-0900","authenticated-orcid":false,"given":"Ching-Ya","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-4129","authenticated-orcid":false,"given":"Chuang-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Cancer Vaccine & Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen 361028, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7378-4235","authenticated-orcid":false,"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Cancer Vaccine & Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen 361028, China"},{"name":"Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung 204, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-4008","authenticated-orcid":false,"given":"Wei-Ti","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen 361028, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-7557","authenticated-orcid":false,"given":"Ya-Ching","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-Yee","family":"Hui","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Cancer Vaccine & Immune Cell Therapy Core Laboratory, Department of Medical Research, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Chang Gung Immunology Consortium, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Department of Dermatology, Xiamen Chang Gung Hospital, Xiamen 361028, China"},{"name":"Immune-Oncology Center of Excellence, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan"},{"name":"Whole-Genome Research Core Laboratory of Human Diseases, Chang Gung Memorial Hospital, Keelung 204, Taiwan"},{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Keelung Branch, Keelung 204, Taiwan"},{"name":"Department of Dermatology, Beijing Tsinghua Chang Gung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 100190, China"},{"name":"Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China"},{"name":"Genomic Medicine Core Laboratory, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Capon, F. (2017). The Genetic Basis of Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18122526"},{"key":"ref_2","first-page":"7","article-title":"Comparison of clinical and immunogenetic features in familial versus sporadic psoriatic arthritis","volume":"18","author":"Rahman","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","article-title":"New Frontiers in Psoriatic Disease Research, Part I: Genetics, Environmental Triggers, Immunology, Pathophysiology, and Precision Medicine","volume":"141","author":"Yan","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00403-011-1169-1","article-title":"Innate immunity in the pathogenesis of psoriasis","volume":"303","author":"Sweeney","year":"2011","journal-title":"Arch. Dermatol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sch\u00f6n, M.P. (2019). Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01764"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zhou, X., Chen, Y., Cui, L., Shi, Y., and Guo, C. (2022). Advances in the pathogenesis of psoriasis: From keratinocyte perspective. Cell Death Dis., 13.","DOI":"10.1038\/s41419-022-04523-3"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5732\/cjc.011.10329","article-title":"Multidrug resistance associated proteins in multidrug resistance","volume":"31","author":"Sodani","year":"2012","journal-title":"Chin. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: A perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gr\u017eelj, J., Mlinari\u010d-Ra\u0161\u010dan, I., Marko, P.B., Marovt, M., Gmeiner, T., and \u0160mid, A. (2021). Polymorphisms in GNMT and DNMT3b are asso-ciated with methotrexate treatment outcome in plaque psoriasis. Biomed. Pharmacother., 138.","DOI":"10.1016\/j.biopha.2021.111456"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/jid.2008.16","article-title":"Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis","volume":"128","author":"Warren","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","article-title":"Polymorphisms in Folate, Pyrimidine, and Purine Metabolism Are Associated with Efficacy and Toxicity of Methotrexate in Psoriasis","volume":"127","author":"Campalani","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2133.2008.08898.x","article-title":"Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms","volume":"160","author":"Warren","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8939","DOI":"10.1074\/jbc.M710449200","article-title":"Betaine-Homocysteine S-Methyltransferase-2 Is an S-Methylmethionine-Homocysteine Methyltransferase","volume":"283","author":"Szegedi","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_17","first-page":"4992","article-title":"A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer","volume":"62","author":"Shen","year":"2002","journal-title":"Cancer Res"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-4419-1599-3_2","article-title":"FOXP3 and its role in the immune system","volume":"665","author":"Kim","year":"2009","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00228-017-2255-x","article-title":"Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis","volume":"73","author":"Indhumathi","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2119\/molmed.2010.00243","article-title":"GNMT Expression Increases Hepatic Folate Contents and Folate-Dependent Methionine Synthase-Mediated Homocysteine Remethylation","volume":"17","author":"Wang","year":"2011","journal-title":"Mol. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ced.13100","article-title":"HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment","volume":"42","author":"West","year":"2017","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_22","first-page":"689","article-title":"Genetic markers in methotrexate treatments","volume":"18","author":"Giletti","year":"2018","journal-title":"Pharm. J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zhu, J., Wang, Z., Tao, L., Han, L., Huang, Q., Fang, X., Yang, K., Huang, G., Zheng, Z., and Yawalkar, N. (2022). MTHFR Gene Polymorphism Association With Psoriatic Arthritis Risk and the Efficacy and Hepatotoxicity of Methotrexate in Psoriasis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.869912"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10388","DOI":"10.1074\/jbc.274.15.10388","article-title":"Impaired Membrane Transport in Methotrexate-resistant CCRF-CEM Cells Involves Early Translation Termination and Increased Turnover of a Mutant Reduced Folate Carrier","volume":"274","author":"Wong","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia","volume":"57","author":"Ballesteros","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","first-page":"6109","article-title":"Association of SLCO1B1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia","volume":"8","author":"Li","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/bjd.17704","article-title":"TT genotype of rs10036748 in TNIP1 shows better response to methotrexate in a Chinese population: A prospective cohort study","volume":"181","author":"Yan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/pgs.13.118","article-title":"Current approaches for TYMS polymorphisms and their importance in molecular epidemiology and pharmacogenetics","volume":"14","author":"Lima","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_29","first-page":"593","article-title":"Polymorphisms in the thymidylate synthase and methylenetetra-hydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"11","author":"Kumagai","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","article-title":"Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia","volume":"359","author":"Krajinovic","year":"2002","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1247\/csf.20.191","article-title":"Functional analysis and DNA polymorphism of the tandemly repeated se-quences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase","volume":"20","author":"Horie","year":"1995","journal-title":"Cell Struct. Funct."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1146\/annurev.genom.1.1.507","article-title":"Apolipoprotein E: Far More Than a Lipid Transport Protein","volume":"1","author":"Mahley","year":"2000","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_33","first-page":"272","article-title":"Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling","volume":"1","author":"Oestreicher","year":"2001","journal-title":"Pharm. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2005.06950.x","article-title":"Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin","volume":"154","author":"Campalani","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Zhou, X., He, Y., Kuang, Y., Li, J., Zhang, J., Chen, M., Chen, W., Su, J., Zhao, S., and Liu, P. (2017). Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020295"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-4632.2004.02098.x","article-title":"HLA-DQA1 and DQB1 alleles are associated with genetic susceptibility to psoriasis vulgaris in Chinese Han","volume":"43","author":"Zhang","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zhou, X., He, Y., Kuang, Y., Chen, W., and Zhu, W. (2022). HLA-DQA1 and DQB1 Alleles are Associated with Acitretin Response in Patients with Psoriasis. Front. Biosci., 27.","DOI":"10.31083\/j.fbl2709266"},{"key":"ref_38","first-page":"319","article-title":"HLA-C, DRB1 and DQB1 alleles involved in genetic predisposition to psoriasis vulgaris in the Slovak population","volume":"58","author":"Javor","year":"2012","journal-title":"Folia Microbiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)61675-6","article-title":"HLA-G and NK receptor are expressed in psoriatic skin: A possible pathway for regulating infiltrating T cells?","volume":"159","author":"Aractingi","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/dth.12140","article-title":"HLA-G 14-bp polymorphism: A possible marker of systemic treatment response in psoriasis vulgaris? Preliminary results of a retrospective study","volume":"27","author":"Borghi","year":"2014","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lin, L., Wang, Y., Lu, X., Wang, T., Li, Q., Wang, R., Wu, J., Xu, J., and Du, J. (2022). The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.937490"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.4049\/jimmunol.1403196","article-title":"Epigenetic Downregulation of SFRP4 Contributes to Epidermal Hyperplasia in Psoriasis","volume":"194","author":"Bai","year":"2015","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1468-3083.2009.03181.x","article-title":"Vascular endothelial growth factor in psoriasis: An indicator of disease severity and control","volume":"23","author":"Nofal","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.jid.5700096","article-title":"Interaction between Genetic Control of Vascular Endothelial Growth Factor Production and Retinoid Responsiveness in Psoriasis","volume":"126","author":"Young","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/pme-2017-0085","article-title":"The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis","volume":"15","author":"Chen","year":"2018","journal-title":"Pers. Med."},{"key":"ref_46","first-page":"523","article-title":"A pharmacogenetic study of ABCB1 polymor-phisms and cyclosporine treatment response in patients with psoriasis in the Greek population","volume":"14","author":"Vasilopoulos","year":"2014","journal-title":"Pharm. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Chernov, A., Kilina, D., Smirnova, T., and Galimova, E. (2022). Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Poly-morphisms on the Response to Cyclosporine in Psoriasis Patients. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112441"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/1523-1747.ep12277177","article-title":"Calmodulin Activities Are Significantly Increased in Both Uninvolved and Involved Epidermis in Psoriasis","volume":"85","author":"Mizumoto","year":"1985","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","first-page":"8","article-title":"Protein network and pathway analysis in a pharmacogenetic study of cyclosporine treatment response in Greek patients with psoriasis","volume":"23","author":"Antonatos","year":"2022","journal-title":"Pharm. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1515\/hsz-2021-0250","article-title":"The paracaspase MALT1 in psoriasis","volume":"402","author":"Hailfinger","year":"2021","journal-title":"Biol. Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.berh.2011.10.004","article-title":"Anti-TNF therapy","volume":"25","author":"Thalayasingam","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_52","first-page":"70","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2016","journal-title":"Pharm. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamadermatol.2013.4632","article-title":"The role of Fc\u03b3 receptor polymorphisms in the response to anti\u2013tumor necrosis factor therapy in psoriasis A pharmacogenetic study","volume":"149","author":"Guilabert","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_54","first-page":"237","article-title":"FCGR3A-V158F polymorphism is a dis-ease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNF\u03b1 inhibitors","volume":"17","author":"Mendrinou","year":"2017","journal-title":"Pharm. J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-\u03b1 and Anti-IL-12\/23 Agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_56","first-page":"76","article-title":"IL17RA gene variants and anti-TNF response among psoriasis patients","volume":"18","author":"Batalla","year":"2016","journal-title":"Pharm. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour ne-crosis factor (TNF)-\u03b1 promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-\u03b1 therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_58","first-page":"494","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2017","journal-title":"Pharm. J."},{"key":"ref_59","first-page":"405","article-title":"The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients","volume":"307","author":"Batalla","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sanz-Garcia, A., Reolid, A., Fisas, L., Mu\u00f1oz-Aceituno, E., Llamas-Velasco, M., Sahuquillo-Torralba, A., Botella-Estrada, R., Garc\u00eda-Mart\u00ednez, J., Navarro, R., and Daud\u00e9n, E. (2021). DNA Copy Number Variation Associated with Anti-tumour Necrosis Factor Drug Response and Paradoxical Psoriasiform Reactions in Patients with Moderate-to-severe Psoriasis. Acta Dermato-Venereol., 101.","DOI":"10.2340\/00015555-3794"},{"key":"ref_61","first-page":"336","article-title":"Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharm. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1073\/pnas.0703893104","article-title":"Structure of CD84 provides insight into SLAM family function","volume":"104","author":"Yan","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5980190","DOI":"10.1155\/2020\/5980190","article-title":"Immune Regulation of TNFAIP3 in Psoriasis through Its Association with Th1 and Th17 Cell Differentiation and p38 Activation","volume":"2020","author":"Jiang","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yang, S., Wang, J., Brand, D.D., and Zheng, S.G. (2018). Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Impli-cations. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.00784"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256427","article-title":"Pharmacogenetic Analysis of TNF, TNFRSF1A, and TNFRSF1B Gene Polymorphisms and Prediction of Response to Anti-TNF Therapy in Psoriasis Patients in the Greek Population","volume":"16","author":"Vasilopoulos","year":"2012","journal-title":"Mol. Diagn. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1172\/JCI29441","article-title":"Misbehaving macrophages in the pathogenesis of psoriasis","volume":"116","author":"Clark","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40291-019-00409-x","article-title":"NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis","volume":"23","author":"Batalla","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"E5825","DOI":"10.1073\/pnas.1509971112","article-title":"I\u03baB\u03b6 is a key driver in the development of psoriasis","volume":"112","author":"Johansen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ng.689","article-title":"Genome-wide association study identifies a pso-riasis susceptibility locus at TRAF3IP2","volume":"42","author":"Ellinghaus","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2016.06.631","article-title":"HLA-C*06:02 Allele and Response to IL-12\/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program","volume":"136","author":"Li","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: A retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/bjd.12331","article-title":"Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B\/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12\/23 blocker ustekinumab","volume":"169","author":"Talamonti","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jaad.2015.08.055","article-title":"HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up","volume":"74","author":"Talamonti","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000441719","article-title":"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis","volume":"232","author":"Galluzzo","year":"2015","journal-title":"Dermatology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 Status With Differential Re-sponse to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis","volume":"155","author":"Hannink","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/pgs-2016-0122","article-title":"Pharmacogenetics of usteki-numab in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2217\/pgs.15.107","article-title":"The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/bjd.16705","article-title":"The supreme Study Group Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: Supreme study","volume":"179","author":"Costanzo","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjd.18013","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: Results from extension phase of the SUPREME study","volume":"181","author":"Papini","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e274","DOI":"10.1111\/jdv.14808","article-title":"Therapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: A retrospective case series","volume":"32","author":"Anzengruber","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdv.15787","article-title":"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: Results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"Meulewaeter","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Verbenko, D.A., Karamova, A.E., Artamonova, O.G., Deryabin, D.G., Rakitko, A., Chernitsov, A., Krasnenko, A., Elmuratov, A., Solomka, V.S., and Kubanov, A.A. (2020). Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11010020"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"Cr661","DOI":"10.12659\/MSM.883544","article-title":"Vitamin D receptor gene polymorphisms and haplotypes (Apa I, Bsm I, Fok I, Taq I) in Turkish psoriasis patients","volume":"18","author":"Acikbas","year":"2012","journal-title":"Med. Sci. Monit."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00403-007-0782-5","article-title":"Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients","volume":"299","author":"Karaduman","year":"2007","journal-title":"Arch. Dermatol. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01213011-200505000-00011","article-title":"Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis","volume":"15","author":"Halsall","year":"2005","journal-title":"Pharm. Genom."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1523-1747.1998.00128.x","article-title":"Vitamin D Receptor Polymorphism and Calcipotriol Response in Patients with Psoriasis","volume":"110","author":"Mee","year":"1998","journal-title":"J. Investig. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-002-0293-3","article-title":"Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients","volume":"294","author":"Lee","year":"2002","journal-title":"Arch. Dermatol. Res."},{"key":"ref_91","first-page":"355","article-title":"A study of ApaI and TaqI genotypes of the vitamin D receptor in Egyptian patients with psoriasis","volume":"36","author":"Kamel","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000098576","article-title":"The Efficacy and Safety of Topically Applied Indigo Naturalis Ointment in Patients with Plaque-Type Psoriasis","volume":"214","author":"Lin","year":"2007","journal-title":"Dermatology"},{"key":"ref_93","first-page":"515","article-title":"Psoriasis Patients with Specific HLA-Cw Alleles and Lower Plasma IL-17 Level Show Improved Response to Topical Lindioil Treatment","volume":"15","author":"Lin","year":"2022","journal-title":"Pharm. Pers. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1136\/ard.2004.030775","article-title":"Genetic epidemiology of psoriasis and psoriatic arthritis","volume":"64","author":"Rahman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2340\/0001555562229236","article-title":"Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution","volume":"62","author":"Brandrup","year":"1982","journal-title":"Acta Derm. Venereol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/archderm.1972.01620050011002","article-title":"The genetics of psoriasis","volume":"105","author":"Watson","year":"1972","journal-title":"Arch. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Magee, C., Jethwa, H., FitzGerald, O.M., and Jadon, D.R. (2021). Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis: A systematic review. Ther. Adv. Musculoskelet. Dis., 13.","DOI":"10.1177\/1759720X211014010"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Membrive Jim\u00e9nez, C., P\u00e9rez Ram\u00edrez, C., S\u00e1nchez Mart\u00edn, A., Vieira Maroun, S., Arias Santiago, S.A., Ram\u00edrez Tortosa, M.D.C., and Morales, A.J. (2021). Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med., 11.","DOI":"10.3390\/jpm11040293"},{"key":"ref_100","first-page":"848","article-title":"A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies","volume":"13","author":"Levin","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_101","first-page":"209","article-title":"Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis","volume":"19","author":"Reolid","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/17425255.2016.1194394","article-title":"Pharmacogenetics and pharmacogenomics in psoriasis treatment: Current challenges and future prospects","volume":"12","author":"Sutherland","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjd.15753","article-title":"A systematic review of pharmacogenetic studies on the response to biologics in patients with psoriasis","volume":"178","author":"Coenen","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wang, C.W., Preclaro, I.A.C., Lin, W.H., and Chung, W.H. (2022). An Updated Review of Genetic Associations With Severe Adverse Drug Re-actions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.886377"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2020.08.003","article-title":"Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians","volume":"147","author":"Wang","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/cpt.2716","article-title":"Implementation of NUDT15 Genotyping to Prevent Azathi-oprine-Induced Leukopenia for Patients With Autoimmune Disorders in Chinese Population","volume":"112","author":"Wang","year":"2022","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:16:32Z","timestamp":1760123792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/8\/7329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":107,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24087329"],"URL":"https:\/\/doi.org\/10.3390\/ijms24087329","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]}}}